Preventive Anti-CD2 Treatment does not Impair Parasite Control in a XXXX Toxoplasmosis Model.

@entity1 @entity32 @entity650 @entity19 @entity3138 @entity1960 @entity8923 @entity3744 @entity3204
Targeting @entity1 @entity3138 with the monoclonal antibody (mAb) CB.219 reduces intestinal inflammation in a @entity1960 model where T cells carry @entity1 @entity3138 . Here, we asked whether this mAb has adverse effects on infection control. @entity19 expressing @entity1 @entity3138 on T cells (huCD2tg) were orally infected with @entity3204 ( @entity3204 and treated with the @entity1 @entity3138 -specific mAb CB.219 in a preventive setting. The intestinal @entity3204 loads in CB.219 treated @entity19 did not differ from the control group. Histologically, huCD2tg @entity19 showed moderate @entity32 that did not change with CB.219 treatment. In the ileum, CB.219 treatment reduced the protein levels of interferon-y, transforming growth factor b and @entity650 , whereas @entity8923 mRNA was slightly increased. The infiltration of neutrophils, macrophages, and T cells into the ileum was unaffected by CB.219 treatment. However, CB.219 treatment decreased the numbers of @entity3744 (+) regulatory T cells (Treg) in ileum and liver of huCD2tg @entity19 . This was confirmed in vitro using @entity1 peripheral blood mononuclear cells. Taken together, targeting @entity3138 (+) T cells by the @entity1 @entity3138 mAb CB.219 does not prevent beneficial immune reactions necessary for pathogen control. Further experiments will address gut specificity, underlying mechanisms, and general applicability of CB.219 treatment.
